TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ANAB

AnaptysBio Inc

Healthcare · Biotechnology

55.10$ +1.4% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Cash Flow

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Cash Flow ANAB
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-166.2%
-11.0% -15.0% -21.5% +72.1% +63.2% +8.8% +273.9% +11.7% +1.8% +0.9% +1.1%
+277.5% +92.1% +277.4% +127.5% +24.6% -7.3% +33.5% +78.2% +21.4% +2.5% +5.9%
+33.4% +1.4% +215.2% -109.2% +1,673.1% -83.8% +857.3%
-170.5% -15.1% +386.9% -140.2% -104.7%
+64.1% -79.0% +480.0% +266.6% -24.3% -29.3% +140.1% -73.8% +125.4% -55.6% -75.7%
+70.0% -79.0% +486,016.0% -41.4% -28.1% -58.9% -1,116.7% -34.1% +139.0%
+25,430.0% -100.0% -21.7% -98.7% -83.5% +414.7% +363.3% -522.8% -99.1% +14,949.6%
+100.0% +0.0% -168.8% +0.0% +9.1% -81.7% -100.0%
+701.7% -78.1% +3,289.6% -23.6% -102.0% -80.4% -82.6% -234.7% -204.4%
+52.2% -101.5% +8.2% +77.2% +38.3% +208.7% -273.1% +32.1%
-168.5%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?